Staff Writer – PsychedelicsFN

Business Updates

Filament Health Announces FDA Authorization of First-Even Direct Psilocybin Clinical Trial

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), an exclusively-natural psychedelic drug discovery company, announces FDA authorization to initiate the first clinical trial using naturally-sourced psychedelic…

PhamaTher Selects Partner for Clinical & Commercial Manufacturing of Its Ketamine Products

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, recently announced that it has signed a contract with Alcami Corporation, a global pharmaceutical contract development and manufacturing…

Levitee Labs Partners with Adracare to Support Addiction, Mental Health Treatments

Adracare Inc. (“Adracare”), a Well Health Technologies company (TSX: WELL), recently announced a partnership with Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7), an integrative wellness company with a…

Cybin Completes 74 Pre-Clinical Studies, Plans Event to Review Findings

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN), a biotechnology company focused on the advancement of psychedelic therapeutics, recently announced the completion of its 74th pre-clinical study as part of its ongoing efforts…

Psyched Wellness Finds Potential New Functional Property & Health Benefits in Preliminary Data

Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9), a life sciences company focused on artisanal functional and psychedelic mushrooms, recently found a new potential functional property and health benefit…

Business Updates

Numinus Finalizes Study Design & Protocol for Phase 1 Clinical Trials

Numinus Wellness Inc. (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, recently announced that the study design and protocol for a Phase 1 clinical trial on a naturally derived Psilocybin…

Business Updates

PharmaDrug Begins Trading on the US OTCQB

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF), a specialty pharmaceutical company focused on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, began trading on the OTCQB…

Business Updates

Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce that following discussions with the U.K. Medicines…

Business Updates

Emotional Intelligence Ventures Reg A Raise at $20M, Company Pursues Psylocibin Transdermal Delivery Research, Plans Nutraceutical Mushroom Supplements Launch

Emotional Intelligence Ventures, led by noted investor and exec David Nikzad, are pleased to announce their Regulation A raise is currently at $20,114,949, with more investors coming in daily. Ultimately, they…

Psyched Wellness Announces Preliminary Data Showing Potential New Functional Property and Health Benefit of Amanita Muscaria Mushroom (AME-1) To Inhibit Human Mast Cell Activation

Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased…